{Reference Type}: Journal Article
{Title}: Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study.
{Author}: Sjöström H;van Westen D;Hall S;Tjerkaski J;Westman E;Muehlboeck S;Hansson O;Svenningsson P;Granberg T;
{Journal}: Parkinsonism Relat Disord
{Volume}: 121
{Issue}: 0
{Year}: 2024 Apr 13
{Factor}: 4.402
{DOI}: 10.1016/j.parkreldis.2024.106047
{Abstract}: <B>BACKGROUND: </B>Differentiating Parkinson's disease (PD) from progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) is a common clinical problem. We aimed to apply the T1-/T2-weighted ratio imaging technique, based on standard clinical MRI, to reveal differences in neurodegeneration in three large cohorts.<BR><B>METHODS: </B>Three cohorts, with a total of 405 participants (269 PD, 44 PSP, 38 MSA, 54 controls), were combined and T1/T2-weighted ratio image analyses were carried out. A combination of automatic segmentation and atlas-based ROI were used in this study. The cohorts were combined using the ComBat batch correction procedure.<BR><B>RESULTS: </B>Group differences were found in the putamen (p = 0.040), with higher T1/T2-weighted ratio in this region in PSP compared to PD and healthy controls (p-values 0.010 and 0.007 respectively). Using putaminal T1/T2-weighted ratio for diagnostic separation, a fair performance was found in separating PSP from healthy controls, with an area under the receiver operating characteristic curve of 0.701.<BR><B>CONCLUSIONS: </B>Different patterns of T1/T2-weighted ratio, reflecting differences in underlying pathophysiology, were found between the groups. Since T1/T2-weighted ratio can be applied to standard clinical MRI sequences to allow more quantitative analyses, this seems to be a promising biomarker for diagnostics and treatment evaluation of parkinsonian disorders for clinical trials.